Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report), DENTSPLY SIRONA (XRAY – Research Report) and Bioventus (BVS – Research Report).
DENTSPLY SIRONA (XRAY)
Morgan Stanley analyst Erin Wright maintained a Buy rating on DENTSPLY SIRONA yesterday and set a price target of $39.00. The company’s shares closed last Tuesday at $38.07.
According to TipRanks.com, Wright is a 5-star analyst with an average return of
Currently, the analyst consensus on DENTSPLY SIRONA is a Moderate Buy with an average price target of $38.17, implying a -0.2% downside from current levels. In a report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $41.00 price target.
Bioventus (BVS)
Morgan Stanley analyst Drew Ranieri maintained a Hold rating on Bioventus yesterday. The company’s shares closed last Tuesday at $2.13, close to its 52-week low of $1.65.
According to TipRanks.com, Ranieri has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bioventus.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTK:
- Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
- Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session
- Cytokinetics joins initiative to recognize international Rare Disease Day
- Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
- Cytokinetics management to meet with Cantor Fitzgerald
